Novartis Balance Sheet
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novartis financial position
At the end of fiscal 2025, Novartis reported total assets of $110.95 billion, up 8.5% from a year earlier against total liabilities of $64.40 billion. Shareholders' equity stood at $46.13 billion, or 41.6% of assets. The company held $11.44 billion in cash and equivalents against $1.48 billion of debt, a net cash position of $9.96 billion.
The current ratio (current assets divided by current liabilities) was 1.12, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.03.
Summary generated from market data by MetaCap's automated system. Methodology
Novartis balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 11.44B | 11.46B | 13.39B | 7.52B | 12.41B | 9.66B | 11.11B | 13.27B | 8.86B | 7.01B |
| Inventory | 6.27B | 5.72B | 5.91B | 7.17B | 6.67B | 7.13B | 5.98B | 6.96B | 6.87B | — |
| Total Current Assets | 30.46B | 29.70B | 30.48B | 36.91B | 45.72B | 29.67B | 29.50B | 35.56B | 28.21B | — |
| Property, Plant & Equipment | 10.78B | 9.46B | 9.51B | 10.76B | 11.54B | 12.26B | 12.07B | 15.70B | 16.46B | — |
| Goodwill | 25.57B | 24.76B | 23.34B | 29.30B | 29.59B | 30.00B | 26.52B | 35.29B | 31.75B | — |
| Intangible Assets | 29.41B | 26.91B | 26.88B | 31.64B | 34.18B | 36.81B | 28.79B | 38.72B | 30.00B | — |
| Total Assets | 110.95B | 102.25B | 99.94B | 117.45B | 131.79B | 127.78B | 118.37B | 145.56B | 133.08B | — |
| Short-Term Debt | 1.48B | 4.00B | 2.81B | 3.10B | 3.52B | 3.25B | 2.72B | 3.89B | 1.05B | — |
| Total Current Liabilities | 27.28B | 28.69B | 26.39B | 28.66B | 30.21B | 33.06B | 28.26B | 29.61B | 23.40B | — |
| Total Liabilities | 64.40B | 58.12B | 53.20B | 58.03B | 63.97B | 71.11B | 62.82B | 66.87B | 58.85B | — |
| Shareholders' Equity | 46.13B | 44.05B | 46.67B | 59.34B | 67.66B | 56.60B | 55.47B | 78.61B | 74.17B | 74.89B |
| Total Debt | 1.48B | 4.00B | 2.81B | 3.10B | 3.52B | 3.25B | 2.72B | 3.89B | 1.05B | — |
| Net Cash (Debt) | 9.96B | 7.46B | 10.58B | 4.41B | 8.89B | 6.41B | 8.39B | 9.38B | 7.81B | 7.01B |
| Shares Outstanding | 1.91B | 1.98B | 2.04B | 2.12B | 2.23B | 2.26B | 2.27B | 2.31B | 2.32B | 2.37B |
This table shows 10 annual periods of Novartis's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, inventory, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow NVS's reporting calendar. What is a balance sheet?